載入...
In MDS, is higher risk higher reward?
Patients with higher-risk myelodysplastic syndrome (HR-MDS) are defined by the original or revised International Prognostic Scoring System and specific genetic features. Treatment of HR-MDS is challenging. Allogeneic hematopoietic stem cell transplantation, the only curative approach, is feasible in...
Na minha lista:
| 發表在: | Hematology Am Soc Hematol Educ Program |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913486/ https://ncbi.nlm.nih.gov/pubmed/31808894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000042 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|